In the News
Diversigen Inc. Selected by Nom NomTM as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services
PAUL, MN and OAKLAND, CA, May 22, 2020 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Nom NomTM, a direct-to-consumer pet health
OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
OraSure Technologies, Inc. announces that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled
Validation of our viral metagenomics sequencing and analysis pipeline for SARS-CoV-2 detection
In this article we’re sharing results from the validation study scientists at Diversigen and DNA Genotek undertook to ensure Diversigen’s viral metagenomics capabilities could be
Diversigen bioinformatics team publishes review on the human virome and disease
“The virome is comprised of endogenous retroviruses, eukaryotic viruses, and bacteriophages and is increasingly being recognized as an essential part of the human microbiome. The
“Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases”
“Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are
Nature Communications publishes new research showing that Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection
Nature Communications publishes new research from Joseph Petrosino, PhD, Diversigen Founder and Chief Science Officer, and other leading researchers. Using multidisciplinary approaches, the research report shows that a complex interplay between human milk oligosaccharid[es (HMOs), milk microbiome, and infant gut microbiome impacts neonatal rotavirus infections.